We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Sugar Levels Affect Risks in Type 1 Diabetes

By LabMedica International staff writers
Posted on 11 Sep 2019
Print article
Image: A major new study on the association between blood glucose levels, including HbA1c, and risks of organ impairment in people with type 1 diabetes can make a vital contribution to diabetes care (Photo courtesy of HealthEngine).
Image: A major new study on the association between blood glucose levels, including HbA1c, and risks of organ impairment in people with type 1 diabetes can make a vital contribution to diabetes care (Photo courtesy of HealthEngine).
Type 1 diabetes is the predominant form of diabetes diagnosed in childhood and is characterized by increased blood glucose levels resulting from insulin deficiency. Intensive treatment with better glycemic control has been shown to reduce the risk of retinopathy and nephropathy, with a strong association between glycated hemoglobin (HbA1c) level and diabetes complications.

The evidence for HbA1c levels and diabetes complications is interpreted differently by organizations. Reaching lower HbA1c levels requires greater effort from people with diabetes and their families and can be associated with more stress and possibly an increased risk of hypoglycemia, which in itself can be burdensome and lead to unconsciousness.

Scientists from the University of Gothenburg (Gothenburg, Sweden) and their colleagues included in a study included children and adults with a diagnosis of diabetes for five or less years when first recorded in the registries. Endpoints of retinopathy were classified as any retinopathy, preproliferative diabetic retinopathy or worse, and proliferative diabetic retinopathy. Any retinopathy included any signs of retinopathy.

Microalbuminuria was defined as two positive test results from three samples taken within one year, with an albumin:creatinine ratio of 3-30 mg/mmol or urinary albumin of 20-200 µg/min (20-300 mg/L), and macroalbuminuria as an albumin:creatinine ratio >30 mg/mmol or urinary albumin >200 µg/min (>300 mg/L). Laboratory methods at participating care units for analyzing HbA1c level and albuminuria are regularly checked with central reference samples of HbA1c and albuminuria to ensure high accuracy. The team evaluated HbA1c as a categorical variable (<6.5% (<48 mmol/mol), 6.5-6.9 (48-52 mmol/mol), 7.0-7.4% (53-57 mmol/mol), 7.5-8.6% (58-70 mmol/mol), and >8.6% (>70 mmol/mol) and estimated risk of complications in relation to HbA1c level as a continuous variable for each 1% (10 mmol/mol).

The scientists reported that the mean age of participants was 14.7 years (43.4% female), mean duration of diabetes was 1.3 years, and mean HbA1c level was 8.0% (63.4 mmol/mol). Compared with HbA1c levels 6.5-6.9%, HbA1c levels 7.0-7.4% (53-57 mmol/mol) were associated with an increased risk of any retinopathy (1.31, 1.05 to 1.64) and microalbuminuria (1.55, 1.03 to 2.32). In Sweden, the target HbA1c value in people with type 1 diabetes is 52 mmol/mol or below, and 47 or lower in children. Elsewhere in the world, the guidelines range from 48 to 58 mmol/mol, and are often higher in children than in adults.

The authors concluded that the risk of retinopathy and nephropathy did not differ at HbA1c levels <6.5% but increased for severe hypoglycemia compared with HbA1c levels 6.5-6.9%. The risk for severe complications mainly occurred at HbA1c levels >8.6%, but for milder complications was increased at HbA1c levels >7.0%.

Marcus Lind, MD, PhD, a Professor of Diabetology and first author of the study, said, “We were unable to see that fewer instances of organ damage occurred at these lower levels. As for loss of consciousness and cramp, which are unusual, low blood glucose caused a 30% rise in risk. Patients with low HbA1c need to make sure they do not have excessively low glucose levels, fluctuations or efforts in managing their diabetes.” The study was published on August 28, 2019, in the journal BMJ.

Related Links:
University of Gothenburg

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.